載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$1.97
−US$0.055 · -2.72%
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
收盤時
US$1.97
−US$0.055 · -2.72%
盤後
US$1.97
US$0.00 · 0.00%
10月12日 下午4:10 ET
盤中時間採用ET。市場資料可能有所延遲。
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
日內區間
目前US$1.97
52週區間
目前US$1.97
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
59
合理估值
情緒
52
多空交錯
風險
53
風險偏高
動能
34
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
日內區間
目前US$1.97
52週區間
目前US$1.97
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年1月6日 | 1:20 | — | — |
股票分割 | 2020年12月9日 | 1:10 | — | — |
股票分割 | 2018年8月13日 | 1:20 | — | — |
股票分割 | 2017年8月29日 | 1:20 | — | — |
股票分割 | 2016年10月28日 | 1:12 | — | — |
股票分割 | 2016年7月1日 | 1:12 | — | — |
已生效 2023年1月6日
1:20
已生效 2020年12月9日
1:10
已生效 2018年8月13日
1:20
已生效 2017年8月29日
1:20
已生效 2016年10月28日
1:12
已生效 2016年7月1日
1:12
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI38.7萬0.00%2.3兆 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF21.1萬0.00%954億 USD0.05%US$233.52-0.63%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.27萬0.00%455.91億 USD0.17%US$84.43-0.01%
Dimensional - US Core Equity 2 ETFDFAC1.18萬0.00%885.96億 USD0.21%US$45.31-0.04%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.11萬0.00%61.81億 USD0.26%US$68.32+0.06%
Dimensional - US Sustainability Core 1 ETFDFSU9730.130.00%23.92億 USD0.15%US$48.13+0.04%
Dimensional - US Small Cap ETFDFAS8914.050.00%338.69億 USD0.31%US$78.17-0.23%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFU.S. Core Equity 1 Portfolio ETF Class SharesDCORDimensional - US Core Equity 2 ETFDFACU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Sustainability Core 1 ETFDFSUDimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
